Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma

Weekly ixazomib with lenalidomide‐dexamethasone (Rd) is feasible and has shown activity in newly diagnosed multiple myeloma (NDMM) patients. This phase 1/2 study (NCT01383928) evaluated the recommended phase 2 dose (RP2D), pharmacokinetics, safety and efficacy of twice‐weekly ixazomib plus Rd in NDM...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Paul G., Hofmeister, Craig C., Rosenbaum, Cara A., Htut, Myo, Vesole, David H., Berdeja, Jesus G., Liedtke, Michaela, Chari, Ajai, Smith, Stephen D., Lebovic, Daniel, Raje, Noopur, Byrne, Catriona, Liao, Eileen, Gupta, Neeraj, Bacco, Alessandra Di, Estevam, Jose, Berg, Deborah, Baz, Rachid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055619/
https://www.ncbi.nlm.nih.gov/pubmed/29938772
http://dx.doi.org/10.1111/bjh.15394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055619/
https://www.ncbi.nlm.nih.gov/pubmed/29938772
http://dx.doi.org/10.1111/bjh.15394

Ejemplares similares